Avas Pharmaceuticals SRL

Mumbai: Avas Pharmaceuticals has officially launched Lupin’s orphan drug NaMuscla (mexiletine) in Italy, aimed at the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. Under the terms of their partnership, Avas will initially commercialize NaMuscla as a Class C (Tier 2), while Lupin is in ongoing discussions with AIFA (Agenzia Italiana del Farmaco) regarding the drug’s reimbursement in Italy. Thierry Volle, President EMEA at Lupin, said, “Our collaboration with Avas allows us to introduce the first licensed treatment for myotonia in Italy and ensures continued access to this essential medication. This partnership reflects Lupin’s commitment to addressing unmet medical needs in rare diseases across Europe.” Marco Rago, President of the Board of Directors, Avas Pharmaceuticals, added, "This collaboration will improve the quality of life for individuals affected by NDM in Italy by ensuring access to top-tier therapeutic solutions.” NDM disorders are a rare group of inherited neuromuscular conditions, characterized by the inability to relax muscles after voluntary contraction. Lupin’s NaMuscla reduces myotonia symptoms in individuals with NDM and has been granted orphan drug status , receiving EU marketing authorization in December 2018. By Online Bureau ,